A Study of IDP-001 in Advanced or Metastatic Solid Tumors
2026年9月2日 更新者:InduPro, Inc.
A Phase 1/2 Open-label Study of IDP-001 in Advanced or Metastatic Squamous Cell Lung Cancer and Other Solid Tumors
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).
研究概览
研究类型
介入性
注册 (估计的)
132
阶段
- 阶段2
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:InduPro Inc.
- 电话号码:617-798-1770
- 邮箱:clinicaltrials@induprotx.com
学习地点
-
-
California
-
Los Angeles、California、美国、90025
- 招聘中
- START Los Angeles
-
接触:
-
首席研究员:
- Navid Hafez, M.D.
-
-
Florida
-
Sarasota、Florida、美国、34232
- 招聘中
- Florida Cancer Specialists
-
接触:
- 电话号码:941-377-9993
- 邮箱:clinicaltrials@flcancer.com
-
首席研究员:
- Manish Patel, M.D.
-
-
Indiana
-
Indianapolis、Indiana、美国、46250
- 招聘中
- Community Cancer Center North
-
接触:
- Adam Norris
- 电话号码:317-621-3858
- 邮箱:anorris@ecommunity.com
-
首席研究员:
- Nikhil Shukla, M.D.
-
-
New York
-
Buffalo、New York、美国、14263
- 招聘中
- Roswell Park Cancer Institute
-
首席研究员:
- Prantesh Jain, M.D.
-
接触:
- 电话号码:1-800-767-9355
- 邮箱:AskRoswell@RoswellPark.org
-
Lake Success、New York、美国、11042
- 招聘中
- START New York Long Island
-
接触:
-
首席研究员:
- Geraldine O'Sullivan-Coyne, M.D.
-
-
Texas
-
Fort Worth、Texas、美国、76104
- 招聘中
- START Dallas Forth Worth
-
接触:
-
首席研究员:
- Salwan Al-Mutar, M.D.
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Histologically-confirmed advanced, metastatic, or recurrent solid tumors that is not amenable to surgical resection or other approved therapeutic options
- Satisfy requirements for prior treatments per tumor type as outlined in the protocol
- Measurable disease per RECIST v1.1
- Participant willing to provide tumor biopsies
- Adequate organ function
- Agree to contraception requirements as outlined in the protocol
- Life expectancy greater than 12 weeks
Exclusion Criteria:
- Any clinically significant cardiac disease
- Any clinically significant corneal disorder
- Known, active, and uncontrolled hepatitis B virus (HBV), hepatitis virus (HCV) or human immunodeficiency virus (HIV), or uncontrolled chronic or ongoing infectious requiring intravenous treatment.
- Active significant neurologic disorders
- Requires home oxygen
- Active autoimmune disease
- History or active skin disease requiring frequent treatment
- History of major immunologic reaction to prior immunoglobulin G-containing agent
- Clinically significant ascites or liver disease
- Uncontrolled diabetes or diabetic neuropathy
- Active bleeding disorders
- Participation in a concurrent clinical study in the treatment period
- Pregnant or lactating or planning to become pregnant
- Known hypersensitivity to IDP-001 or any of its ingredients
- Unresolved toxicities from previous anticancer therapy
- Has had a seizure prior to Screening
- Prior solid organ transplant or allogeneic stem cell transplant
- Current endocrinopathy
- History of Stevens-Johnson syndrome or Toxic Epidermal Necrolysis
- History or interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids
- Stroke or transient ischemic attack prior to Screening
- Participant has any other condition or illness that, in the opinion of the Investigator, may compromise participant safety, compliance, or interfere with the conduct and evaluation of the current study.
Note: Other inclusion and exclusion criteria may apply.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase 1 Part 1 Dose Escalation
Participants with advanced or metastatic solid tumors will receive IDP-001 as intravenous (IV) infusion.
|
IV infusion
|
|
实验性的:Phase 1 Part 2 Indication Selection
Participants with a single tumor indication will receive IDP-001 as IV infusion
|
IV infusion
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Phase 1 Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) during Cycle 1
大体时间:3 weeks
|
3 weeks
|
|
Phase 1 Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Dose Reduction, Dose Interruption, and Dose Discontinuation
大体时间:Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator
大体时间:Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Duration of Response (DOR) per RECIST Version 1.1 as Assessed by Investigator
大体时间:Approximately 6 months
|
Approximately 6 months
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Area Under the Concentration Time Curve (AUC) of IDP-001
大体时间:Approximately 6 months
|
Approximately 6 months
|
|
Maximum Observed Plasma Concentration (Cmax) of IDP-001
大体时间:Approximately 6 months
|
Approximately 6 months
|
|
Number of Participants with Anti-drug Antibodies (ADAs) in Blood
大体时间:Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 1: ORR per RECIST Version 1.1 as Assessed by Investigator
大体时间:Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 1: DOR per RECIST Version 1.1 as Assessed by Investigator
大体时间:Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Dose Reduction, Dose Interruption, and Dose Discontinuation
大体时间:Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Disease Control Rate (DCR) per RECIST Version 1.1 as Assessed by Investigator
大体时间:Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Time to Response (TTR) per RECIST Version 1.1 as Assessed by Investigator
大体时间:Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Progression Free Survival (PFS) per RECIST Version 1.1 as Assessed by Investigator
大体时间:Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Overall Survival (OS)
大体时间:Approximately 18 months
|
Approximately 18 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年7月8日
初级完成 (估计的)
2028年6月1日
研究完成 (估计的)
2028年12月1日
研究注册日期
首次提交
2026年5月8日
首先提交符合 QC 标准的
2026年5月19日
首次发布 (实际的)
2026年5月22日
研究记录更新
最后更新发布 (实际的)
2026年9月3日
上次提交的符合 QC 标准的更新
2026年9月2日
最后验证
2026年7月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- IDP-001-101
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.